Platelet Rich Plasma Market Size & Trend Report, 2022-2030
The global Platelet Rich Plasma market size was estimated at USD 560.9 Million in 2021 and is expected to surpass around USD 2.1 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 15.20% during the forecast period 2022 to 2030.
Growth Factors:
Platelet-rich plasma usage is witnessing growth owing to the increasing participation in sporting events leading to the increasing cases of sports injuries and an upsurge in cosmetic surgery. Increasing research applications of platelet rich plasma (PRP) are also fueling the industry growth. For instance, in 2020, according to the American Society of Plastic Surgeons, a 25% rise in the use of PRP in cosmetics was observed in the last 4 years.
In March 2020, the WHO declared COVID-19 a global pandemic. This outbreak has considerably affected the global market. In response to the COVID-19 outbreak, governments of various countries and states announced protective or preventative actions, such as imposing restrictions. As COVID-19 had reached almost everywhere during the last two weeks of March 2020, its far-reaching consequences were supply chain disruption, constraints in resource allocation, and hindrances in patient treatment activities among other reasons, which resulted in the decline in demand. However, by January 2021, the market stabilized and continued to recover in terms of demand and supply.
In recent years, there has been a spurt in demand for use of platelet-rich plasma in the treatment of sports injuries, orthopedic disorders, and musculoskeletal conditions. It concentrates on growth factors and can significantly improve healing time. Regenerative medicines too have PRP as an important source of custom products for each patient, supporting wound healing and repair cascade.
Platelet-rich plasma has evolved in plastic surgery. It has promising results to utilize the body’s own natural tissue repair process to achieve improved form and function. The characteristics such as ease of use, inexpensive to produce utilizing patient’s cells, and little or no risk of adverse reactions are the major reasons behind the rising adoption of PRP in treatments.
Platelet-rich plasma has multiple utilities in skin rejuvenation, improving skin texture and color, and lighting wrinkles depth. Currently, evidence has shown micro-needling and topical application of PRP in improving collagen production and skin tightening for vampire facials. It has also emerged in application in skin pigmentation disorders and treating acne scars. In hair transplants, PRP can bind to growth factors and elevates the proliferation of human derma papilla cells leading to the formation and maintenance of hair follicles. Thus, PRP has a growing number of uses leading to an increase in market growth.
Wound healing, bone formation of bisphosphonate-based osteonecrosis of the jaw, and soft tissue healing in the alveolar socket after tooth removal are promising results of PRP. Moreover, medicinal factors are anticipated to generate several therapeutic expansion opportunities, thus driving the market in the future.
Report Scope of the Platelet Rich Plasma Market
|
Report Coverage |
Details |
|
Market Size |
US$ 2.1Billion by 2030 |
|
Growth Rate |
CAGR of 15.20% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Type, application, end-use and Region, |
|
Companies Mentioned |
Johnson & Johnson; Arthrex, Inc.; EmCyte Corporation; DR. PRP AMERICA, LLC; Juventix; Terumo Corporation; Zimmer Biomet; Stryker; Apex Biologix; Celling Biosciences |
Type Insights
Pure platelet-rich plasma held the largest revenue share of over 50.2% in 2021 due to its widespread use in the healing process, tissue repair, and regeneration. PRP offers minimum risk and adverse effects due to allergic and immune responses in treatments. It is mostly known for its off-label use and manufacturers are interested to develop different products, which are expected to boost the industry growth.
The leucocyte-rich segment has the potential to grow due to its increasing utility across general surgery, orthopedic, and sports injuries. The segment is expected to expand at a CAGR of 15.65% from 2022 to 2030. Evidence has demonstrated that LR-PRP is effective in bone regeneration and the non-surgical management of knee osteoarthritis, which is anticipated to fuel market growth in the forecast period.
Application Insights
The orthopedics segment has the largest revenue share of over 25.4% in 2021. However, other segments such as dermatology, sports medicine, and ulcer healing are expected to grow at a lucrative CAGR during the forecast period. In comparison to conventional treatments, PRP has favorable results for effective healing in chronic tendon injuries. PRP in orthopedic therapeutics is conveniently used because of improved healing, tissue repair, and regeneration. Moreover, PRP offers long-lasting relief, soft tissue reconstruction, and bone reconstruction, thus leading to market growth.
The sports medicine segment has shown growth because of the autogenous advantage of PRP-based treatment, investigated safety profile, ease of preparation, and reduced cost of preparation. In addition, it fulfills the need for rapid recovery so that sportspersons can return to the field, which fuels the market growth.
The dermatology segment is anticipated to grow at a faster rate during the forecast period owing to cosmetic surgeries and expanding use in ulcer treatment. PRP-based micro-needling in cosmetic procedures has driven market demand and is expected to fuel market growth. In the case of chronic ulcers, treatment with PRP reduces ulcer size and completely heals ulcer wounds.
End-use Insights
Hospitals held the largest revenue share of over 45.4% in 2021. This can be attributed to a rapid expansion of PRP-based therapies in hospitals owing to the increasing new osteoarthritis cases in recent years, high demand for non-surgical management in treatment, and rising hair loss incidences.
Companies such as Focus Technology Co. and Changsha Biomed Supply Co. are supporting by providing the installation of centrifuge systems in hospitals, which further creates lucrative opportunities for industry growth. The others segment is projected to expand at a higher CAGR during the forecast period.
Regional Insights
North America was the largest revenue-generating region with a share of over 40.2% in 2021. This can be attributed to the presence of a large number of manufacturing units interested in developing novel approaches with PRP-based treatments, high procurement at end-users such as hospitals and clinics, and the presence of key market players. Furthermore, regulatory authorities are supporting and granting approvals, which strengthened the market presence. Such activities are expected to contribute to expanding the platelet-rich plasma available in the market and boost growth.
In Europe, Germany held a considerable revenue share in 2021 owing to strong research facilities for platelet-rich plasma. For instance, in 2020, a survey called ‘Working Group for Clinical Tissue Generation’ was studied, which demonstrated the need for PRP preparation Standardization and its application protocols for indications such as knee osteoarthritis. The availability of a large number of manufacturers and service providers in the region will further drive the market.
The Asia Pacific region is expected to be the fastest-growing region during the forecast period due to the rising number of cosmetic surgeries, the growing interest in research and academic institutes, and increasing government support for healthcare developments.
Some of the prominent players in the Platelet Rich Plasma Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Platelet Rich Plasma market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Platelet Rich Plasma Market Study:
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and Forecast Timeline
1.3 Information Procurement
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Purchased Database
1.5.2 Nova one advisor’s Internal Database
1.5.3 Secondary Sources
1.5.4 Primary Research
1.5.5 Details of Primary Research
1.6 Information or Data Analysis
1.6.1 Platelet Rich Plasma (PRP) Market: segment revenue and growth analysis
1.6.2 sports medicine market: segment revenue and growth analysis
1.6.3 Platelet Rich Plasma (PRP)-based ulcer healing Market: segment revenue and growth analysis
1.6.3.1 Platelet Rich Plasma (PRP)-based ulcer healing Market: segment definition
1.6.3.1.1 Non-Healing Ulcers
1.6.3.1.1.1 Diabetic Ulcers
1.6.3.1.1.2 Pressure Ulcers
1.6.3.1.1.3 Pyoderma gangrenosum
1.6.3.1.1.4 Venous ulcers
1.6.4 Data Analysis Models
1.7 Market Formulation & Validation
1.8 Model Details
1.8.1 Commodity Flow Analysis
1.8.1.1 Approach 1: Commodity Flow Approach
1.8.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.9 Market: CAGR Calculation
1.10 List of Secondary Sources
1.11 List of Primary Sources
1.12 Objectives
1.12.1 Objective 1
1.12.2 Objective 2
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Market Summary
Chapter 4 Host Cell Contaminant Testing Market Variables, Trends & Scope
4.1 Market Trends & Outlook
4.2 Market Segmentation & Scope
4.3 Market Driver Analysis
4.3.1 Rise In The Incidence Of Orthopedic Disorders And Sports Injuries
4.3.2 Increasing Regulatory Focus On Host Cell Contaminant Detection
4.3.3 extending Medical Applications Of Platelet Rich Plasma
4.3.4 Increasing Number Of Evidence-Based Studies For Prp-Based Wound Healing
4.4 Market Restraint Analysis
4.4.1 high Costs Associated With Prp Products
4.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
4.6 Porter’s Five Forces Analysis
4.7 COVID-19 Impact Analysis
4.8 Penetration & Growth Prospect Mapping
Chapter 5 Platelet Rich Plasma Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)
5.1 Platelet Rich PlasmaMarket: Type Movement Analysis
5.2 Pure PRP
5.2.1 Pure Prpmarket Estimates And Forecast, 2018 - 2030 (USD Million)
5.3 leukocyte Rich Prp
5.3.1 leukocyte Rich Prpmarket Estimates And Forecast, 2018 - 2030 (USD Million)
5.4 Others
5.4.1 Other Type Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Platelet Rich Plasma market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
6.1 platelet Rich Plasmamarket: Application Movement Analysis
6.2 Orthopedics
6.2.1 Orthopedics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3 Sports Medicine
6.3.1 Sport Medicine market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4 Cosmetic Surgery
6.4.1 Platelet Rich Plasma (Prp) Market Estimates And Forecast For Cosmetic Surgery, 2018 - 2030
6.5 Dermatology
6.5.1 Coverage Scenario: U.S. Centers For Medicare & Medicaid Services
6.5.2 Platelet Rich Plasma (Prp) Market Estimates And Forecast For Dermatology, 2018 - 2030
6.5.3 Ulcer healing
6.5.3.1 Platelet Rich Plasma (PRP) Market estimates and forecast for ulcer healing, 2018 - 2030
6.5.3.2 Venous ulcers
6.5.3.2.1 Platelet Rich Plasma (PRP) Market estimates and forecast for venous ulcers, 2018 - 2030
6.5.3.3 Traumatic ulcers
6.5.3.3.1 Platelet Rich Plasma (PRP) Market estimates and forecast for traumatic ulcers, 2018 - 2030
6.5.3.4 Pyoderma gangrenosum ulcers
6.5.3.4.1 Platelet Rich Plasma (PRP) Market estimates and forecast for pyoderma gangrenosum ulcers, 2018 - 2030
6.5.3.5 Diabetic ulcers
6.5.3.5.1 Platelet Rich Plasma (PRP) Market estimates and forecast for diabetic ulcers, 2018 - 2030
6.5.3.6 Trophic ulcers
6.5.3.6.1 Platelet Rich Plasma (PRP) Market estimates and forecast for trophic ulcers, 2018 - 2030
6.5.3.7 Vasculitic ulcers
6.5.3.7.1 Platelet Rich Plasma (PRP) Market estimates and forecast for vasculitic ulcers, 2018 - 2030
6.5.4 Others
6.5.4.1 Platelet Rich Plasma (PRP) Market estimates and forecast for others, 2018 - 2030
6.6 Ophthalmic Surgery
6.6.1 Platelet Rich Plasma (Prp) Market Estimates And Forecast For Ophthalmic Surgery, 2018 - 2030
6.7 Neurosurgery
6.7.1 Platelet Rich Plasma (Prp) Market Estimates And Forecast For Neurosurgery, 2018 - 2030
6.8 General Surgery
6.8.1 Platelet Rich Plasma (Prp) Market Estimates And Forecast For General Surgery, 2018 - 2030
6.9 Others
6.9.1 Platelet Rich Plasma (Prp) Market Estimates And Forecast For Others, 2018 - 2030
Chapter 7 Platelet Rich Plasma (PRP) Market - Segment Analysis, by End-use, 2018 - 2030 (USD Million)
7.1 Platelet Rich Plasma (PRP): End-use Movement Analysis
7.2 Hospitals
7.2.1 Hospitals market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3 Clinics
7.3.1 Clinics market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Others
7.4.1 Others market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Platelet Rich Plasma (PRP) Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)
8.1 Platelet Rich Plasma (PRP) Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.2 Germany
8.3.2.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.3 U.K.
8.3.3.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.4 Spain
8.3.4.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.5 France
8.3.5.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.6 Italy
8.3.6.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.4 India
8.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.5 South Korea
8.4.5.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.6 Australia
8.4.6.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6 Middle East And Africa
8.6.1 Middle-East And Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.3 UAE
8.6.3.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.4 Saudi Arabia
8.6.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Company Profile
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.3.1 Johnson & Johnson
9.3.1.1 Company overview
9.3.1.2 DePuy Synthes
9.3.1.2.1 Company overview
9.3.1.3 Financial Performance
9.3.1.4 Product benchmarking
9.3.1.5 Strategic initiatives
9.3.2 Arthrex, Inc.
9.3.2.1 Company overview
9.3.2.2 Financial Performance
9.3.2.3 Product benchmarking
9.3.2.4 Strategic initiatives
9.3.3 EmCyte Corporation
9.3.3.1 Company overview
9.3.3.2 Product benchmarking
9.3.3.3 Strategic initiatives
9.3.4 DR. PRP AMERICA, LLC
9.3.4.1 Company overview
9.3.4.2 Product benchmarking
9.3.5 Juventix
9.3.5.1 Company overview
9.3.5.2 Financial Performance
9.3.5.3 Product benchmarking
9.3.6 Terumo Corporation
9.3.6.1 Company overview
9.3.6.2 TERUMO BCT, INC.
9.3.6.2.1 Company overview
9.3.6.3 Financial Performance
9.3.6.4 Product benchmarking
9.3.6.5 Strategic initiatives
9.3.7 Zimmer Biomet
9.3.7.1 Company overview
9.3.7.2 Financial Performance
9.3.7.3 Product benchmarking
9.3.7.4 Strategic initiatives
9.3.8 Stryker
9.3.8.1 Company overview
9.3.8.2 Financial Performance
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 Apex Biologix
9.3.9.1 Company overview
9.3.9.2 Financial Performance
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Celling Biosciences
9.3.10.1 Company overview
9.3.10.2 Financial Performance
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers